Cargando…
Ebola Virus Transmission Initiated by Systemic Ebola Virus Disease Relapse
During the 2018-2020 Nord Kivu Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo, an individual who had received the Merck rVSV-ZEBOV vaccine was diagnosed with EVD. His treatment included an Ebola virus-specific monoclonal antibody (mAb114), and he recovered within 14 days...
Ejemplares similares
-
Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context
por: Nkuba-Ndaye, Antoine, et al.
Publicado: (2022) -
Efficiency of Field Laboratories for Ebola Virus Disease Outbreak during Chronic Insecurity, Eastern Democratic Republic of the Congo, 2018–2020
por: Mukadi-Bamuleka, Daniel, et al.
Publicado: (2023) -
Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection
por: Tshiani Mbaya, Olivier, et al.
Publicado: (2021) -
Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak
por: Tshomba, Antoine Oloma, et al.
Publicado: (2022) -
843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics
por: Mulangu, Sabue
Publicado: (2019)